See more : Wialan Technologies, Inc. (WLAN) Income Statement Analysis – Financial Results
Complete financial analysis of Avicanna Inc. (AVCNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avicanna Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Neinor Homes, S.A. (NNRHF) Income Statement Analysis – Financial Results
- Salmon Evolution ASA (SALME.OL) Income Statement Analysis – Financial Results
- PCCW Limited (PCWLF) Income Statement Analysis – Financial Results
- Tenaga Nasional Berhad (5347.KL) Income Statement Analysis – Financial Results
- Brightcom Group Limited (BCG.NS) Income Statement Analysis – Financial Results
Avicanna Inc. (AVCNF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.avicanna.com
About Avicanna Inc.
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.79M | 4.05M | 3.27M | 1.57M | 168.25K | 117.97K | 26.66K | 0.00 |
| Cost of Revenue | 10.13M | 2.93M | 437.09K | 2.14M | 76.11K | 172.71K | 0.00 | 0.00 |
| Gross Profit | 6.66M | 1.12M | 2.83M | -570.12K | 92.14K | -54.73K | 26.66K | 0.00 |
| Gross Profit Ratio | 39.66% | 27.55% | 86.63% | -36.31% | 54.76% | -46.40% | 100.00% | 0.00% |
| Research & Development | 330.66K | 276.94K | 304.31K | 376.27K | 1.22M | 456.62K | 23.68K | 0.00 |
| General & Administrative | 11.34M | 9.61M | 12.53M | 15.82M | 20.53M | 7.56M | 2.48M | 27.12K |
| Selling & Marketing | 2.16M | 380.08K | 345.91K | 425.64K | 649.32K | 248.73K | 43.92K | 2.71K |
| SG&A | 13.50M | 9.99M | 12.88M | 16.24M | 21.18M | 7.81M | 2.53M | 29.83K |
| Other Expenses | -7.17M | -168.61K | 580.29K | 454.76K | 383.42K | 180.48K | 0.00 | 0.00 |
| Operating Expenses | 6.66M | 11.53M | 14.25M | 18.42M | 23.32M | 8.44M | 2.61M | 29.83K |
| Cost & Expenses | 24.72M | 14.46M | 14.68M | 20.56M | 23.39M | 8.44M | 2.61M | 29.83K |
| Interest Income | 0.00 | 1.67M | 738.06K | 1.00 | 68.93K | 10.36K | 1.45K | 0.00 |
| Interest Expense | 610.26K | 1.67M | 738.06K | 263.11K | 54.76K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 777.29K | 887.33K | 893.99K | 1.09M | 923.51K | 172.71K | 63.24K | 357.98K |
| EBITDA | -7.36M | -12.18M | -15.13M | -17.45M | -22.27M | -8.27M | -2.52M | 0.00 |
| EBITDA Ratio | -43.80% | -239.43% | -304.05% | -1,111.21% | -12,985.12% | -7,647.89% | -9,448.37% | 0.00% |
| Operating Income | -7.93M | -10.58M | -10.83M | -18.53M | -22.77M | -9.20M | -2.58M | -29.83K |
| Operating Income Ratio | -47.24% | -261.35% | -331.40% | -1,180.44% | -13,534.01% | -7,794.29% | -9,685.58% | 0.00% |
| Total Other Income/Expenses | -809.99K | -4.94M | -5.94M | -16.77M | -22.85K | 1.16M | -17.30K | 0.00 |
| Income Before Tax | -8.74M | -14.74M | -16.76M | -35.05M | -23.25M | -7.29M | -2.60M | -29.83K |
| Income Before Tax Ratio | -52.07% | -364.02% | -512.73% | -2,232.35% | -13,816.44% | -6,178.97% | -9,750.46% | 0.00% |
| Income Tax Expense | 0.00 | 1.50M | 13.77K | -2.19M | -1.03M | -1.07M | 1.76K | -357.99K |
| Net Income | -8.74M | -14.74M | -16.77M | -32.86M | -21.07M | -7.10M | -2.60M | -29.83K |
| Net Income Ratio | -52.07% | -364.02% | -513.15% | -2,093.02% | -12,524.06% | -6,017.63% | -9,750.46% | 0.00% |
| EPS | -0.10 | -0.25 | -0.41 | -1.12 | -1.05 | -0.45 | -0.19 | 0.00 |
| EPS Diluted | -0.10 | -0.25 | -0.41 | -1.12 | -1.05 | -0.45 | -0.19 | 0.00 |
| Weighted Avg Shares Out | 84.71M | 59.17M | 41.29M | 29.40M | 20.05M | 15.65M | 13.59M | 10.88M |
| Weighted Avg Shares Out (Dil) | 84.71M | 59.17M | 41.29M | 29.40M | 20.05M | 15.65M | 13.59M | 10.88M |
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company
Avicanna Reports Q3 2024
Avicanna Announces Closing of Non-Brokered Private Placement
ThreeD Capital Inc. Issues Early Warning Report in Connection with Acquisition of Securities of Avicanna Inc.
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
Avicanna Announces Repayment of Debentures
Avicanna Announces Closing of Non-Brokered Private Placement
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
Avicanna Reports Q2 2024
Source: https://incomestatements.info
Category: Stock Reports